Brighter Has Launched Its Initial Public Offering Period

Brighter AB (publ) has launched its Initial Public Offering period at AktieTorget as promised. The company has developed and patented the world’s first all-in-one self-care device for diabetics that does not need to be attached to the body: Brighter One TM. Now, the public is offered a unique opportunity to take part in Brighter’s future growth through the IPO.

After the listing, Brighter plans to complete the production plants that are required to start the production of the company’s patented self-care systems. These compose a production series that will ease the lives of, to start with, 350 000 diabetics in Sweden.

"Brighter’s products take with their technology a unique holistic approach for diabetes care. We are glad to get to be a part of the process already now, since we believe that this will become a success” says Mikael Cederhag, founder and owner of Rubin Medical. “Rubin strives to offer high quality products that simplify life for diabetics, and Brighter offers precisely this for injection-treated diabetics.”

Five good reasons to invest in Brighter

• 75 per cent of all insulin-treated diabetics want an integrated technical device for self-care. No player has so far offered the diabetics such an all-in-one solution.

• Brighter has developed and obtained patent on the world’s first all-in-one self-care solution for diabetics that does not need to be attached to the body. The primary target group for this product series, Brighter One™, consists of 14 million diabetics in Europe and USA – a market with an annual turnover of approximately 25 billion SEK and that grows by 5-10% per year.

• The critical technical components are licensed in and already included in both FDA-approved and CE-marked products. Brighter has attained a technical “proof of concept” and carried out a detailed cost assessment for ingoing goods and production.

• Brighter is ready for production adjustment and with the on-going IPO, the production of the production line is assured.

• The sales channels are ready for the Nordic markets thanks to cooperation with Rubin Medical – one of the Nordic countries' largest distributors of diabetes devices as well as appointed as a Gazelle company by Dagens Industri the last two years.

The offer in summary

Rights Issue: Private placement to present shareholders and to the public
IPO issue price: SEK 3.20 per share
Minimum purchase: 1 000 shares
IPO period: August 15 – September 26, 2011
Amount of shares issued: 2 656 000
Gross issue size: MSEK 8.5
"Pre-money" valuation of the company: MSEK 32

For further information, please visit the company’s website www.BrighterCompany.com or AktieTorget’s website www.AktieTorget.se, where invitation, memorandum and issuing form can be downloaded.

About Brighter AB (publ

Brighter develops and commercializes innovative solutions for diabetes self-cafe. It is a STING Alumni company. Financing has come from state and institutional investors such as ALMI, Innovationsbron, KAS Innovationsfond (an activity within the Karl-Adam Bonnier foundation) as well as from private investors.

During the period August 15 to September 26, there is a unique opportunity to issue shares in Brighter. After the introduction issuing, Brighter will be listed at AktieTorget. For more information: www.BrighterCompany.com.

Brighter's all-in-one solution: Brighter One TM Full Video

About Rubin Medical AB

Rubin Medical markets products within diabetes care in the Nordic countries. They work primarily within the segment insulin pumps where they are market leaders. They have been appointed as Gazelle company by the newspaper Dagens Industri the last 2 years. For more information: www.RubinMedical.se.

Contact Information

http://www.BrighterCompany.com

http://www.BrighterCompany.com/video

http://www.facebook.com/brightercompany

http://twitter.com/Brighter_AB

Phone: +46 8 55 00 88 20

Fax: +46 8 55 00 88 30

Truls Sjöstedt, CEO at Brighter AB (publ)

Phone: +46 709 73 46 00

Email: truls.sjostedt@brightercompany.com